L’Oreal Partnership with Organovo

L’Oreal USA, the largest subsidiary of the world’s leading beauty company, has announced a partnership with 3-D bioprinting company Organovo Holdings, Inc. (NYSE MKT: ONVO). Developed between L’Oreal’s U.S.-based global Technology Incubator and Organovo, the collaboration will leverage Organovo’s proprietary NovoGen Bioprinting Platform and L’Oreal’s expertise in skin engineering to develop 3-D printed skin tissue for product evaluation and other areas of advanced research.

This partnership marks the first-ever application of Organovo’s groundbreaking technology within the beauty industry. «We developed our technology incubator to uncover disruptive innovations across industries that have the potential to transform the beauty business,» said Guive Balooch, Global Vice President of L’Oreal’s Technology Incubator.  «Organovo has broken new ground with 3-D bioprinting, an area that complements L’Oreal’s pioneering work in the research and application of reconstructed skin for the past 30 years. Our partnership will not only bring about new advanced in vitro methods for evaluating product safety and performance, but the potential for where this new field of technology and research can take us is boundless.»

Organovo’s 3D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. «We are excited to be partnering with L’Oreal, whose leadership in the beauty industry is rooted in scientific innovation and a deep commitment to research and development,» said Keith Murphy, Chairman and Chief Executive Officer at Organovo. «This partnership is a great next step to expand the applications of Organovo’s 3-D bioprinting technology and to create value for both L’Oreal and Organovo by building new breakthroughs in skin modeling.»

L’Oreal USA is the largest subsidiary of the L’Oreal Group, the worldwide leader in beauty. L’Oreal USA manages a portfolio of 30 iconic beauty brands, including Clarisonic, Essie, Garnier, Giorgio Armani Beauty, Kerastase, Kiehl’s, Lancome, L’Oreal Paris, Matrix, Maybelline New York, NYX, Redken, Soft-Sheen Carson, Urban Decay and Yves Saint Laurent Beaute. In addition to its corporate headquarters in New York City, L’Oreal USA has research, manufacturing and distribution facilities across 13 other states including Arkansas, California, Florida, Kentucky, New Jersey, Ohio, Texas and Washington with a workforce of more than 10,000 employees.

Organovo designs and creates functional, three-dimensional human tissues for use in medical research, cosmetic, and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, cosmetic, and academic partners. Organovo’s 3D human tissues have the potential to accelerate the discovery process, enabling drug treatments and active agents to be developed faster and at lower cost.